PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
1183629452	rs3219151	PMID:24061200	GABRA6	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.587	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184137748	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:22331680	CYP2C19	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is not associated with metabolism of phenobarbital in infants with Seizures as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	no	= 0.811	13		Unknown	Metabolism/PK	true	No significant differences were seen in PK parameters between infants with the CYP2C19 *1/*1 diplotype (extensive metabolizers), *1/*2, *1/*3 (heterozygous extensive metabolizers), or poor metabolizers (*2/*2 or *2/*3 diplotypes). PK parameters examined = phenobarbital concentration, volume of distribution and clearance. 3 variants were genotyped = rs4244285 681G>A, rs4986893 636G>A, 991A>G.	phenobarbital
1444702812	rs1045642	PMID:25846690	ABCB1	Genotype GG is associated with increased resistance to phenobarbital in people with Epilepsy as compared to genotype AA.	yes	= 0.039	62	48	East Asian	Efficacy	false	Patients with PB-resistant epilepsy had a significantly higher frequency of ABCB1 3435CC (rs1045642GG) genotype and had focal epilepsy more often than patients with PB-responsive epilepsy.	phenobarbital
981954817	rs2032582	PMID:18812236	ABCB1	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
769146001	rs2032582	PMID:20417680	ABCB1	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	no		228		Central/South Asian	Efficacy	false	"This is a three allele SNP.  No association was found between any of the three alleles (C,T,A) and response to antiepileptic drugs.
Subjects on the different medications were pooled."	carbamazepine; phenobarbital; phenytoin; valproic acid
981954829	rs1045642	PMID:18812236	ABCB1	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1183701191	HLA-DRB1*04:10:01	PMID:24236482	HLA-DRB1	HLA-DRB1 *04:10:01 is not associated with Stevens-Johnson Syndrome when treated with phenobarbital.	no	= 0.1036	8	2878	East Asian	Toxicity	false	Phenotype:  Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction. The allele used here represents *04:10.	phenobarbital
769146005	rs1045642	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		282		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
1183629441	rs2279020	PMID:24061200	GABRA1	Allele A is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	no	= 0.8361	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184987951	HLA-B*15:02:01	PMID:23551241	HLA-B	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenobarbital in children.	no	= 0.18	20	20	East Asian	Toxicity	true	Children who carried the *15:02 allele did not have an increased risk of developing phenobarbital-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).	phenobarbital
1451120240	rs1801133	PMCID:PMC6689870	MTHFR	Genotype AA is associated with increased risk of Psychotic Disorders due to phenobarbital and phenytoin in men with Epilepsy.	no		1		Unknown	Toxicity	false	Case report of a patient who developed psychotic symptoms following initiation of treatment with phenytoin and phenobarbital. Patient was found to have the AA genotype and had several vitamin deficiencies. Psychotic symptoms improved with vitamin supplementation and switching phenytoin and phenobarbital treatment to lamotrigine, although the patient still experienced monthly seizures. Please note that alleles have been complemented to the positive strand.	phenobarbital; phenytoin
982047879	CYP2C19*2	PMID:23551241	CYP2C19	CYP2C19 *2 is associated with increased risk of severe cutaneous adverse drug reactions when treated with phenobarbital in children as compared to CYP2C19 *1.	yes	= 0.03	40	40	East Asian	Toxicity	true		phenobarbital
981954839	rs2032582	PMID:18812236	ABCB1	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1184755407	HLA-B*15:02:01	PMID:19018717	HLA-B	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	not stated	= 1.0E-4	18		East Asian	Toxicity	false	This allele was not observed in any of the patients.	carbamazepine; phenobarbital; phenytoin; zonisamide
769146060	rs2606345	PMID:21121773	CYP1A1	Allele A is associated with increased risk of Seizures when treated with carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele C.	yes	= 0.00297	101		Central/South Asian	Efficacy,Metabolism/PK	false	This association was found in women but not in men.  The authors postulate that this is modulated through metabolism of estradiol.	carbamazepine; phenobarbital; phenytoin; valproic acid
981751120	rs17183814	PMCID:PMC2767285	SCN2A	Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	yes	= 0.06	336	160	Central/South Asian	Efficacy	false	p value was above significance level after correction for multiple testing.  Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	carbamazepine; phenobarbital; phenytoin; valproic acid
769145998	rs1128503	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		228		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184469071	HLA-B*15:02:01	PMID:24496695	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.	yes	= 0.043	6	32	East Asian	Toxicity	true	Children with aromatic antiepileptic-induced Stevens-Johnson Syndrome had a higher frequency of the *15:02 allele, as compared to antiepileptic-tolerant controls and healthy population controls.	carbamazepine; oxcarbazepine; phenobarbital
1184746954	HLA-B*13:01:01	PMID:19002350	HLA-B	HLA-B *13:01:01 is associated with Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine, phenobarbital or phenytoin in people with severe cutaneous adverse reactions.	no		4	16	East Asian	Toxicity	false	The frequency of the *1301 allele (25%) was higher compared to the frequency reported for the general population (1.3%) but was not statistically significant after correction for multiple comparisons.	carbamazepine; phenobarbital; phenytoin
1183629461	rs211037	PMID:24061200	GABRG2	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.718	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184988858	HLA-B*15:02:01	PMID:22429379	HLA-B	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	not stated		2		East Asian	Toxicity	false	Case report with two female Han Chinese patients. The first patient developed maculopapular rash after receiving carbamazepine and then again after receiving oxcarbazepine. No rash occurred after treatment with levetiracetam. The second patient developed Stevens-Johnson Syndrome after receiving phenytoin, then developed a maculopapular eruption after receiving phenobarbital and then again after receiving carbamazepine. No reaction occurred after treatment with topiramate. The authors state that this study reports cross-reactivity to these anti-epileptics.	carbamazepine; oxcarbazepine; phenobarbital; phenytoin
1183629456	rs2229944	PMID:24061200	GABRB2	Allele G is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele A.	no	= 0.1233	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
981954797	rs1128503	PMID:18812236	ABCB1	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1183701152	HLA-B*51:01:01	PMID:24236482	HLA-B	HLA-B *51:01:01 is associated with Stevens-Johnson Syndrome when treated with phenobarbital.	yes	= 0.0042	16	2878	East Asian	Toxicity	false	Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The allele used here represents *51:01.	phenobarbital
1183701181	HLA-A*24:20	PMID:24236482	HLA-A	HLA-A *24:20 is not associated with Stevens-Johnson Syndrome when treated with phenobarbital.	no	= 0.1036	8	2878	East Asian	Toxicity	false	Phenotype:  Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction.	phenobarbital
981954805	rs2032582	PMID:18812236	ABCB1	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1184755431	HLA-B*07:02:01	PMID:19018717	HLA-B	HLA-B *07:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	not stated	= 1.0E-4	18		East Asian	Toxicity	false	This allele was not observed in any of the patients.	carbamazepine; phenobarbital; phenytoin; zonisamide
1184987994	HLA-B*15:02:01	PMID:23551241	HLA-B	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine, phenobarbital or phenytoin in children.	no	= 0.53	40	40	East Asian	Toxicity	true	Carbamazepine n=3, phenobarbital n=20, phenytoin n=17. Children who carried the *15:02 allele did not have an increased risk of developing antiepileptic-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Negative results were also seen when considering phenobarbital and phenytoin subgroups.	carbamazepine; phenobarbital; phenytoin
1183680883	HLA-B*15:02:01	PMID:23692434	HLA-B	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with phenobarbital in people with Epilepsy.	no	= 1.0	2	10	East Asian	Toxicity	false	Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele did NOT have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 2 cases were compared against 10 controls; cases developed SJS/TEN on phenobarbital, controls did not.  p < 0.01 was considered significant, after adjustment for multiple comparisons using Bonferroni's correction.	phenobarbital
982047671	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:22331680	CYP2C19	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is not associated with metabolism of phenobarbital in infants with Seizures as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	no	= 0.761	31		Unknown	Metabolism/PK	true	No significant differences were seen in PK parameters between infants with the CYP2C19 *1/*1 diplotype (extensive metabolizers), *1/*2, *1/*3 (heterozygous extensive metabolizers), or poor metabolizers (*2/*2 or *2/*3 diplotypes). PK parameters examined = phenobarbital concentration, volume of distribution and clearance. 3 variants were genotyped = rs4244285 681G>A, rs4986893 636G>A, 991A>G.	phenobarbital